Bernad Daniel M, Dal Pra Alan, Baule Cintia, Frey Benicio N, Faria Sergio
Department of Oncology, Division of Radiation Oncology, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Can J Urol. 2013 Aug;20(4):6868-70.
Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders. We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such findings. This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT.
雄激素剥夺疗法（ADT）常用于前列腺癌的治疗，且与包括精神障碍在内的多种副作用相关。我们报告了一例不寻常的病例，一名62岁患有高危前列腺癌的男性在开始使用促黄体生成素释放激素（LHRH）激动剂后出现了新发精神病，并讨论了解释此类发现的可能机制。本病例报告强调了在接受ADT治疗的前列腺癌患者中持续评估和监测潜在情绪和行为症状的重要性。
